Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae to announce first quarter 2015 financial results and host conference call May 12, 2015

Invitae to announce first quarter 2015 financial results and host conference call May 12, 2015

April 28, 2015

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its first quarter 2015 financial results on Tuesday, May 12, 2015. Invitae’s management team will host a conference call on Tuesday, May 12, 2015 at 4:45 p.m. ET/1:45 p.m. PT to discuss the financial results and recent developments.

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and ...

Read more


Invitae appoints Robert Nussbaum, M.D. as Chief Medical Officer

Invitae appoints Robert Nussbaum, M.D. as Chief Medical Officer

April 27, 2015

Medical genetics pioneer from UCSF to join executive team to lead medical organization

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the appointment of Robert L. Nussbaum, M.D. as Chief Medical Officer; such appointment will become effective August 1, 2015. As a board-certified internist and medical geneticist, Dr. Nussbaum has dedicated his career to improving the care of adults and children with hereditary disorders.

Dr. Nussbaum was most recently chief of the Division of ...

Read more


Invitae presents new data demonstrating use of next-generation sequencing for multi-gene panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

Invitae presents new data demonstrating use of next-generation sequencing for multi-gene panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

March 26, 2015

Company also expands test catalog; now offers full coverage of CHEK2 gene and four new cancer-related genes

SALT LAKE CITY and SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, is presenting seven posters at the 2015 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, including data demonstrating the use of next-generation sequencing (NGS) technology in genetic testing, a proposed variant classification system based on ACMG guidelines and genetic testing case studies.

Invitae also announced that ...

Read more


Invitae to present seven posters highlighting new data on the use of next-generation sequencing for multi-gene panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

Invitae to present seven posters highlighting new data on the use of next-generation sequencing for multi-gene panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting

March 17, 2015

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, today announced it will be presenting seven posters at the 2015 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Salt Lake City. 

The titles and schedule of the poster presentations are as follows:

Poster Session 1: Thursday, March 26, 10:30 am – 12:00 pm MT

  • Poster #105: Next-Generation Panel vs. Traditional BRCA1/2 Testing: Challenging Variants, Classification Under the Draft ACMG ISV Guidelines and Potential ...

Read more


Invitae announces fourth quarter and 2014 year-end financial results and highlights and provides 2015 outlook

Invitae announces fourth quarter and 2014 year-end financial results and highlights and provides 2015 outlook

March 10, 2015

-- Company demonstrates early progress towards achieving its goal of making genetic information more affordable and accessible --

SAN FRANCISCO, March 10, 2015 -- Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the fourth quarter and year ended December 31, 2014. Highlights for the quarter and year include:

  • Delivered more than 1,800 billable reports in the fourth quarter and more than 3,600 billable reports during 2014.
  • Improved cost of goods sold (COGS) by driving the average cost per ...

Read more


Invitae to announce fourth quarter and year-end 2014 financial results and host conference call on March 10, 2015

Invitae to announce fourth quarter and year-end 2014 financial results and host conference call on March 10, 2015

February 24, 2015

SAN FRANCISCO, February 24, 2015 – Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its fourth quarter and year-end 2014 financial results on Tuesday, March 10, 2015. Invitae’s management team will host a conference call on Tuesday, March 10, 2015 at 4:45 p.m. ET/1:45 p.m. PT to discuss the financial results and recent developments.

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international ...

Read more


Invitae announces completion of initial public offering and full exercise of underwriters’ option to purchase additional shares

Invitae announces completion of initial public offering and full exercise of underwriters’ option to purchase additional shares

February 18, 2015

SAN FRANCISCO, February 18, 2015 – Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the closing of its initial public offering of 7,302,500 shares of common stock at an initial public offering price of $16.00 per share, which included 952,500 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock. Total gross proceeds from the offering were approximately $116.8 million, before deducting ...

Read more


 Invitae announces pricing of initial public offering of common stock

Invitae announces pricing of initial public offering of common stock

February 11, 2015

SAN FRANCISCO, February 11, 2015 – Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the pricing of its initial public offering of 6,350,000 shares of its common stock at an initial offering price of $16.00 per share, for total gross proceeds of $101.6 million before deducting underwriting discounts and commissions and other offering expenses.  The shares of Invitae’s common stock are expected to begin trading on the New York Stock Exchange under the ...

Read more


Invitae announces settlement in lawsuit with Myriad Genetics

Invitae announces settlement in lawsuit with Myriad Genetics

January 26, 2015

SAN FRANCISCOJanuary 26, 2015—Invitae Corporation, a genetic information company, announced today that it had reached a settlement with Myriad Genetics, Inc., the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, and Endorecherche, Inc. in their patent dispute concerning Invitae’s genetic testing for the BRCA1, BRCA2 and MUTYH genes (MDL Case No. 2:14-CV-02510; Civil Case No. 2:14-cv-00153-RJS (D. Utah).)

The parties agreed to dismiss with prejudice ...

Read more


Invitae Corporation files registration statement for proposed initial public offering

Invitae Corporation files registration statement for proposed initial public offering

January 09, 2015

SAN FRANCISCO January 9, 2015—Invitae Corporation announced today that it has filed a registration statement on Form S‐1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Invitae intends to apply to list its common stock on The New York Stock Exchange under the symbol “NVTA ...

Read more